Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-05-24
2011-05-24
Marschel, Ardin (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S506000, C514S478000, C514S490000
Reexamination Certificate
active
07947670
ABSTRACT:
Provided herein, inter alia, are solid forms of geldanamycin analogs, pharmaceutical compositions comprising a geldanamycin analog and a crystallization inhibitor, methods of making and using such compositions. Additionally, provided are methods for the treatment of cancer, a neoplastic disease state and/or a hyperproliferative disorder, and methods of inhibiting Heat Shock Protein 90 (“Hsp90”).
REFERENCES:
patent: 4261989 (1981-04-01), Sasaki et al.
patent: 5387584 (1995-02-01), Schnur
patent: 5834472 (1998-11-01), Sangekar et al.
patent: 5932566 (1999-08-01), Schnur et al.
patent: 6548555 (2003-04-01), Curatolo et al.
patent: 6872715 (2005-03-01), Santi et al.
patent: 6964978 (2005-11-01), Hageman et al.
patent: 7115279 (2006-10-01), Curatolo et al.
patent: 7235260 (2007-06-01), Crew et al.
patent: 7282493 (2007-10-01), Adams et al.
patent: 7361647 (2008-04-01), Adams et al.
patent: 7375217 (2008-05-01), Adams et al.
patent: 7465718 (2008-12-01), Zhang et al.
patent: 2002/0009494 (2002-01-01), Curatolo et al.
patent: 2003/0072801 (2003-04-01), Curatolo et al.
patent: 2003/0211144 (2003-11-01), Tabibi et al.
patent: 2003/0219489 (2003-11-01), Curatolo et al.
patent: 2003/0228358 (2003-12-01), Perlman et al.
patent: 2004/0013734 (2004-01-01), Babcock et al.
patent: 2005/0176695 (2005-08-01), Zhang et al.
patent: 2005/0203612 (2005-09-01), Bhat et al.
patent: 2005/0256097 (2005-11-01), Zhong et al.
patent: 2006/0003011 (2006-01-01), Crew et al.
patent: 2006/0014730 (2006-01-01), Ulm et al.
patent: 2006/0019939 (2006-01-01), Adams et al.
patent: 2006/0019941 (2006-01-01), Adams et al.
patent: 2006/0067953 (2006-03-01), Mansfield et al.
patent: 2006/0205705 (2006-09-01), Ross et al.
patent: 2006/0228405 (2006-10-01), Ulm et al.
patent: 2006/0252739 (2006-11-01), Johnson et al.
patent: 2006/0252740 (2006-11-01), Johnson et al.
patent: 2007/0026072 (2007-02-01), Olsen et al.
patent: 2007/0148232 (2007-06-01), Crew et al.
patent: 2009/0042847 (2009-02-01), Licari et al.
patent: 0577215 (2000-03-01), None
patent: 1027887 (2000-08-01), None
patent: 0901786 (2007-06-01), None
patent: 2106111 (1983-04-01), None
patent: WO-93/14215 (1993-07-01), None
patent: WO-95/01342 (1995-01-01), None
patent: WO-98/08490 (1998-03-01), None
patent: WO-00/03737 (2000-01-01), None
patent: WO-00/37050 (2000-06-01), None
patent: WO-03/013430 (2003-02-01), None
patent: WO-03/026571 (2003-04-01), None
patent: WO-03/066005 (2003-08-01), None
patent: WO-03/086381 (2003-10-01), None
patent: WO-2004/082676 (2004-09-01), None
patent: WO-2005/063714 (2005-07-01), None
patent: WO-2005/095347 (2005-10-01), None
patent: WO-2005/112587 (2005-12-01), None
patent: WO-2006/034147 (2006-03-01), None
patent: WO-2006/050457 (2006-05-01), None
patent: WO-2006/089207 (2006-08-01), None
patent: WO-2006/094029 (2006-09-01), None
patent: WO-2006/118953 (2006-11-01), None
patent: WO-2007/001049 (2007-01-01), None
patent: WO-2007/002093 (2007-01-01), None
patent: WO-2007/009007 (2007-01-01), None
patent: WO-2007/053284 (2007-05-01), None
patent: WO-2007/059116 (2007-05-01), None
patent: WO-2007/064926 (2007-06-01), None
patent: WO-2007/084233 (2007-07-01), None
patent: WO-2007/084233 (2007-07-01), None
Tian et al., Bioorganic & Medicinal Chemistry, 2004, vol. 12, pp. 5317-5329.
Yagi et al., Chemical and Pharmaceutical Bulletin, 1996, vol. 44(1), pp. 241-244.
Marin et al., Farmaco, 2002, vol. 57(9), pp. 723-727; Abstract only.
Honkanen et al., European Journal of Pharmaceutical Sciences, 2002, vol. 15, pp. 479-488.
Kai et al., Chemical & Pharmaceutical Bulletin, 1996, vol. 44(3), pp. 568-571.
Tanno et al., Drug Development and Industrial Pharmacy, 2004, vol. 30(1), pp. 9-17.
Kaur et al., “Antiangiogenic Properties of 17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin: An Orally Bioavailable Heat Shock Protein 90 Modulator”;Clinical Cancer Research(2004) 10:4813-4821.
Egorin et al., “Plasma Pharmacokinetics And Tissue Distribution of 17-(Allylamino)-17-Demethoxygeldanamycin (NSC 330507) In CD2F1 Mice1”;Cancer Chemother Pharmacol(2001) 47:291-302.
Buchner, J., “Hsp90—A Holding for Folding”Trends Biochem. Sci. (1999) 24:136-141.
Clevenger et al., “Design, Synthesis and Evaluation of a Radicicol and Geldanamycin Chimera, Radamide”Organic Letters(2004) 6:4459-4462.
Egorin et al., “Metabolism of 17-(Allylamino)-17-Demethoxygeldanamycin (NSC 330507) by Murine and Human Hepatic Preparations”Cancer Research(1998) 58:2385-2396.
Grem et al., “Phase I and Pharmacologic Study of 17-(Allylamino)-17-Demethoxygeldanamycin in Adult Patients with Solid Tumors”J. Clin. Oncol. (2005) 23:1805-1893.
Guo et al., “Formation of 17-Allylaminodemethoxygeldanamycin (17-AAG) Hydroquinone by NAD(P)H:Quinone Oxireductase 1: Role of 17-AAG Hydroquinone in Heat Shock Protein 90 Inhibition”Cancer Research(2005) 65:10006-10015.
Hancock and Parks, “What is the True Solubility Advantage for Amorphous Pharmaceuticals?”Pharmaceutical Research(2000) 17:397-404.
Hancock and Zografi, “Characteristics and Significance of the Amorphous State in Pharmaceutical Systems”J. Pharm. Sci. (1997) 86:1-12.
Hu et al., “Isolation and Characterization of Novel Geldanamycin Analogues”J. Antibiotics(2004) 57:421-428.
Kelland et al., “DT-Diaphorase Expression and Tumor Cell Sensitivity to 127-Allylamino, 17-Demethyoxygeldanamycin, an Inhibitor of Heat Shock Protein 90”J. Nat. Can. Inst. (1999) 91:1940-1949.
Kumar and Mishra, “Analgesic, Anti-Inflammatory and Ulcerogenic Studies of Meloxicam Solid Dispersions in Rodents”Iranian Journal of Pharmacology and Therapeutics(2006) 5:77-79.
Konno and Taylor “Ability of Different Polymers to Inhibit Crystallization of Amorphous Felodipine in the Presence of Moisture”Pharmaceutical Research(2008) 25:969-978.
Kushida et al., “Improvement of Dissolution and Oral Absorption of ER-34122, A Poorly Water-Soluble Dual 5-Lipoxygenase/Cyclooxygenase Inhibitor with Anti-Inflammatory Activity by Preparing Solid Dispersion”J. Pharm. Sci. (2002) 91:258-266.
Lang et al., “Biotransformation of Geldanamycin and 17-Allylamino-17-Demethoxygeldanamycin by Human Liver Microsomes: Reductive Versus Oxidative Metabolism and Implications”Drug Metabolism and Disposition(2007) 35:21-29 andDrug Metabolism and Disposition Fast Forward, published on Sep. 29, 2006, 40 pages.
Leuner and Dresssman, “Improving Drug Solubility for Oral Delivery Using Solid Dispersions”Eur. J. Pharm. Biopharm. (2000) 50:47-60.
Li et al., “Effects of Geldanamycin and Its Derivatives on RNA-Directed DNA Polymerase and Infectivity of Rauscher Leukemia Virus”Cancer Treatment Reports(1977) 61:815-824.
Maloney et al., “Hsp90 as a New Therapeutic Target for Cancer Therapy: The Story Unfolds”Expert Opin. Biol. Ther. (2002) 2: 3-24.
Marsac et al., “A Comparison of the Physical Stability of Amorphous Felodipine and Nifedipine Systems”Pharmaceutical Research(2006) 23:2306-2316.
Mitsiades et al., “Antimyeloma Activity of Heat Shock Protein-90 Inhibition”Blood(2006) 107:1092-1100.
Overhoff et al., “Effect of Stabilizer on the Maximum Degree and Extent of Supersaturation and Oral Absorption of Tacrolimus Made by Ultra-Rapid Freezing”Pharmaceutical Research(2008) 25:167-175.
Patterson et al., “Preparation of Glass Solutions of Three Poorly Water Soluble Drugs by Spray Drying, Melt Extrusion and Ball Milling”International Journal of Pharmaceutics(2007) 336:22-34.
Pignatello et al., “Preparation of Solid Dispersions of Nonsteroidal Anti-inflammaotry Drugs with Acrylic Polymers and Studies on Mechanisms of Drug-Polymer Interactions”AAPS PharmSciTech(2002) 3:1-11.
Rutherford et al., “Hsp90 as a Capacitator for Morphological Variation”Nature(1998) 396:336-342.
Sasaki et al., “Growth Inhibition of Virus Transformed Cells In Vitro and Antitumor Activi
Austad Brian C.
Grenier Louis
Holson Edward B.
Lee John J.
Pak Roger H.
Engelenner Thomas J.
Infinity Pharmaceuticals Inc.
Marschel Ardin
Mollaaghababa Reza
Nutter McClennan & Fish LLP
LandOfFree
Ansamycin formulations and methods of use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ansamycin formulations and methods of use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ansamycin formulations and methods of use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2678080